About
Cytokine-derived therapeutic candidates
Areas of Focus
Categories
Biologics & BiopharmaceuticalNJ, NY, PA
Team (9)
Albert Dyrness
Sonnet BioTherapeutics
team_member
Donald Griffith
Chief Financial Officer
Sonnet BioTherapeutics
executive
John K. Cini, Ph.D.
Chief Scientific Officer & Co-Founder
Sonnet BioTherapeutics
executivefounder
Lori McNeill
Sonnet BioTherapeutics
team_member
Nailesh Bhatt
Sonnet BioTherapeutics
team_member
Raghu Rao
Interim Chief Executive Officer
Sonnet BioTherapeutics
executive
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
242
By Phase
PHASE1/PHASE2: 2EARLY_PHASE1: 1PHASE1: 1
By Status
RECRUITING: 1TERMINATED: 1COMPLETED: 1UNKNOWN: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT05756907Lead Sponsor
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
PHASE1/PHASE2Recruiting
165 participants
Started: Sep 15, 2023 · Completed: May 30, 2025
NCT05435742Lead Sponsor
SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)
PHASE1/PHASE2Terminated
9 participants
Started: Oct 27, 2022 · Completed: Mar 17, 2024
NCT05408572Lead Sponsor
Study of SON-1010 (IL12-FHAB) in Healthy Adults
EARLY_PHASE1Completed
32 participants
Started: Jul 27, 2022 · Completed: May 17, 2023
NCT05352750Lead Sponsor
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
PHASE1Unknown
36 participants
Started: Apr 20, 2022 · Completed: Dec 31, 2024
Locations (1)
Headquarters
Princeton, NJ, United States
Map
Loading map...